CCDC18-AS1: A Potential Drug Target and Biomarker (G100131564)

Target Name: CCDC18-AS1

NCBI ID: G100131564

CCDC18-AS1

Other Name(s): CCDC18 antisense RNA 1

CCDC18-AS1: A Potential Drug Target and Biomarker

CDC18-AS1 is a protein that is expressed in various tissues of the body, including the lungs, heart, kidneys, and intestines. It is a member of the CCDC gene family, which is known for producing proteins that play a critical role in cell signaling and inflammation. One of the functions of CDC18-AS1 is to regulate the production of pro-inflammatory cytokines, which can contribute to the development of various diseases, including cancer.

CDC18-AS1 Interacts with Other Proteins

CDC18-AS1 has been shown to interact with several other proteins, including but not limited to:

1. NF-kappa-B2: This is a transcription factor that plays a critical role in cell signaling and inflammation. CDC18-AS1 has been shown to physically interact with NF-kappa-B2 and regulate its activity.
2. NF-kappa-B3: This is another transcription factor that is involved in cell signaling and inflammation. It is known to interact with CDC18-AS1 and regulate its activity.
3. TGF-β1: This is a transcription factor that is involved in cell signaling and growth. It is known to interact with CDC18-AS1 and regulate its activity.
4. Platelet-derived growth factor (PDGF): This is a cytokine that can stimulate the growth and differentiation of various cell types. It is known to interact with CDC18-AS1 and regulate its activity.

CDC18-AS1 Regulates Pro-Inflammatory Cytokine Production

CDC18-AS1 has been shown to regulate the production of pro-inflammatory cytokines, which are important mediators of inflammation. These cytokines include but are not limited to:

1. TNF-伪: This is a cytokine that is involved in inflammation and immune responses. It is known to be regulated by CDC18-AS1.
2. IL-1尾: This is a cytokine that is involved in inflammation and immune responses. It is known to be regulated by CDC18-AS1.
3. IL-6: This is a cytokine that is involved in inflammation and immune responses. It is known to be regulated by CDC18-AS1.
4. GIFT: This is a cytokine that is involved in inflammation and immune responses. It is known to be regulated by CDC18-AS1.
5. HIF1伪: This is a transcription factor that is involved in the regulation of inflammation and cellular responses to stress. It is known to be regulated by CDC18-AS1.

CDC18-AS1 as a Potential Drug Target

CDC18-AS1 has been shown to play a critical role in the regulation of pro-inflammatory cytokine production, which can contribute to the development of various diseases, including cancer. Therefore, targeting CDC18-AS1 may be a promising strategy for the development of new treatments for these diseases.

One potential approach to targeting CDC18-AS1 is to use small molecules or antibodies that can inhibit its activity. For example, small molecules that inhibit the activity of CDC18-AS1 have been shown to be effective in treating various diseases, including cancer. Similarly, antibodies that recognize and bind to CDC18-AS1 have been shown to be effective in treating various diseases, including cancer.

Conclusion

In conclusion, CDC18-AS1 is a protein that plays a critical role in the regulation of pro-inflammatory cytokine production, which can contribute to the development of various diseases. Therefore, targeting CDC18-AS1 with small molecules or antibodies may be a promising strategy for the development of new treatments for these diseases. Further research is needed to fully understand the role of CDC18-AS1 and to develop effective treatments.

Protein Name: CCDC18 Antisense RNA 1

The "CCDC18-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC18-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets